Our goal at Collidion Inc. is to create immediate to long-term value for our partners through the repositioning of drugs and medical devices that would otherwise remain undervalued.

 

Collidion is a healthcare company with a focus on external innovation by covering various segments of the international healthcare market. The company intends to build a strong and transformative portfolio of healthcare assets through;

  • Acquisition or licensing both drugs and devices at various stages of development
  • Development of such assets into stand-alone subsidiaries
  • Provide broad-spectrum operational, regulatory and management support
  • Participate in subsequent funding, partnering and merger and acquisition activities

 

Anti-Infectives  

Our key area of interest is to partner and develop licensed technologies from external companies to help combat antibiotic resistance in the healthcare setting.   

 

Collidion's Core Areas of Focus

  • Combat Antibiotic Resistance

  • Specific Drugs to Eradicate Biofilms

  • Delivery Systems for Systemic Use

  • Delivery Systems for Topical Use


“Why is antimicrobial resistance a global concern?
...Without effective anti-infective treatment, many standard medical treatments will fail or turn into very high risk procedures.”
— World Health Organization, Antimicrobial Resistance Fact Sheet. http://www.who.int/mediacentre/factsheets/fs194/en/
“Antimicrobial resistance jeopardizes health care gains to society.
The achievements of modern medicine are put at risk by antimicrobial resistance. Without effective antimicrobials for prevention and treatment of infections, the success of organ transplantation, cancer chemotherapy and major surgery would be compromised.”
— World Health Organization, Antimicrobial Resistance Fact Sheet. http://www.who.int/mediacentre/factsheets/fs194/en/